HOLD with hedged execution; defined entries at $272 and $303+, hard stop $271, re-evaluate post-Oct 21 Q3 print
HOLD existing exposure with 2.5-3% hedge upgrade. The convergence of all three analysts (Aggressive, Neutral, Conservative) on HOLD is empirically correct given $288 entry with 13 days to Oct 21 binary catalyst, 27x forward P/E pricing in $10.64 delivery requiring sustained sequential acceleration, and momentum-loss signals at upper Bollinger resistance. Do not add at current levels—the entry R/R is symmetric-to-negative. Patience is intellectually honest: Aggressive analyst has not made a case strong enough to override confirmation discipline, and Conservative analyst has not made a case strong enough to abandon a working structural thesis. Use $7B cash, 23-year dividend streak, active buyback, and 4.86x current ratio as cost-of-waiting buffer while defining precise trigger levels for post-catalyst action.
| Position | Action |
|---|---|
| Current price $288 with 13 days to Q3 binary catalyst, 27x forward P/E at upper Bollinger resistance ($297.23 vs $299.96 band) | Do not add; symmetric-to-negative R/R profile warrants maintaining neutral position cap |
| Daily close below $271 (50 SMA structural invalidation of post-September basing pattern) on expanding volume with capitulation signs | Reassess toward Underweight with 30-40% trim on gap reaction |
| Daily close above $303 on above-average volume (>6M) | Convert Hold to Overweight with measured add |
| At $272 with volume exhaustion on 50 SMA test | Recovery-trade entry for scaled add; improves R/R to ~1.5:1 |
| Post-Q3 (Oct 21) beat with Q4 conviction guide | Upgrade to Overweight on next-day weakness |
| Post-Q3 beat with in-line-to-soft guide | Stay Hold |
| Post-Q3 miss or weak guide | Downgrade to Underweight with 30-50% trim on gap reaction |
TXN is in the early innings of a cyclical recovery that hasn't been priced, with accelerating revenue growth (+22.8% YoY), expanding margins (750 bps operating leverage in two quarters), and a fortress balance sheet positioning the stock for multiple expansion as consensus marks up estimates.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | $249.55 | bullish |
| 50 SMA | $271.75 | bullish |
| 10 EMA | $285.86 | neutral |
| MACD Line | +6.53 | bullish |
| MACD Signal Line | +4.49 | bullish |
| MACD Histogram | +2.04 | neutral |
| RSI | 60.81 | bullish |
| Upper Bollinger Band | $299.96 | neutral |
| Middle Bollinger Band (20 SMA) | $276.46 | bullish |
| Lower Bollinger Band | $252.96 | neutral |
| ATR |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Daily close above $303 on above-average volume (>6M) confirming breakout above upper Bollinger band ($299.96)
Then: Measured add from Hold to Overweight
↩ rebuts: “Bear Concern #2: Hawkish Fed is a multiple headwind”
EV: +5-10% near-term to $299.96; $330+ over 12 months · concedes: Fed higher-for-longer partially pressures multiples (granted partially); 5-8% pullback to 10 EMA at $285.86 possible before next leg up; MACD histogram declining from +3.34 to +2.04 indicates short-term momentum loss; Cyclicality exists; high fixed costs remain a theoretical risk
The bull's recovery story is already fully priced at $288 with zero margin of safety, and the tape is showing classic distribution behavior.
EV: ~$213 (-26% from $288 probability-weighted) · concedes: Q4 2025 EPS $1.27 was below Q3 2025 EPS $1.48 (analysts did miss); Q2 2026 EPS $2.14 was a real recovery from trough; CapEx moderation could reflect Lehi fab efficiency, not just constraint; Q4 2025 revenue $4.42B with inventory $4.80B = 100+ days inventory did normalize somewhat to Q2 2026's 77 days; Inventory drawdown from $4.83B to $4.61B is real; Current ratio of 4.86x is strong on surface; 35% ROE is real (for now); 8-10 year customer stickiness is real; Stock did rally 25% from September low
→ vs neutral: The trader's 'two-sided setup' framing is lazy analysis; the data (22.8% revenue growth, 860bps margin expansion, $2.19B FCF, 35.2% ROE) points clearly toward early-cycle recovery, not ambiguity
→ vs neutral: MACD histogram decline from +3.34 to +2.04 represents healthy normalization after parabolic September rally, not distribution; MACD line still at +6.53 confirms uptrend intact
→ vs neutral: October 6 'failure' at upper Bollinger Band ($297.23 vs $299.96) is actually strength pressing against resistance, not a bearish reversal signal
→ vs conservative: 27x forward P/E is not 'fully priced' given only 62% EPS recovery from trough; analog cycle suggests multiple expansion alongside earnings growth into 2027
→ vs conservative: The bear case requires assuming cyclical recovery breaks despite every leading indicator confirming it compounding; that's contrarian beyond what evidence supports
→ vs conservative: Waiting for $272 flush or $303 breakout sacrifices 5% upside while risking a flush that may never come before the October 21 catalyst
→ vs neutral: Polymarket 78% beat signal provides independent corroboration; dismissing it due to thin volume while citing it as bear evidence when convenient is intellectually dishonest
| $8.05 |
| neutral |
| Current Close | $288.20 | bullish |
Support: 285.86 · 276.46 · 271.75 · 252.96 | Resistance: 299.96 · 297.23 · 293.8
TXN maintains a bullish long-term structure with price firmly above the 200 SMA (+15.5%) and 50 SMA (+6.0%), though a short-term consolidation/pullback is underway after the sharp rally from late-September lows. The 10 EMA at $285.86 represents the critical short-term pivot level, while the 50 SMA at $271.75 serves as the medium-term trend line—holds above these levels would keep the constructive bias intact. Momentum is cooling from overbought conditions: MACD histogram has declined from +3.34 to +2.04 and RSI has fallen from 72.37 to 60.81, suggesting the path of least resistance may be consolidation rather than immediate continuation higher. The upper Bollinger Band at $299.96 represents the next resistance breakout trigger, while a close below $271.75 would signal meaningful trend deterioration.
Market Cap
$263.20B
P/E Ratio (TTM)
43.87x
Forward P/E
27.07x
PEG Ratio
1.03
Price/Book
14.61x
EPS (TTM)
$6.57
Forward EPS
$10.64
Dividend Yield
2.10%
Beta
1.339
52-Week High
$334.03
52-Week Low
$152.73
50-Day Avg
$271.44
200-Day Avg
$250.57
Gross Margin (TTM)
~58.3%
Operating Margin (TTM)
42.6%
Net Profit Margin (TTM)
31.1%
EBITDA Margin
~48.9%
Return on Equity (ROE)
35.2%
Return on Assets (ROA)
13.1%
Current Ratio
4.86x
Debt-to-Equity
0.78 (78%)
Free Cash Flow (TTM)
$3.55B
Q2 2026 Revenue
$5,463M
Q2 2026 Gross Profit
$3,352M
Q2 2026 Operating Income
$2,327M
Q2 2026 EBITDA
$2,947M
Q2 2026 Net Income
$1,980M
Q2 2026 Diluted EPS
$2.14
Q2 2026 Operating Cash Flow
$2,703M
Q2 2026 CapEx
($514M)
Q2 2026 Free Cash Flow
$2,189M
Cash & Equivalents (Q2 2026)
$3,660M
Short-Term Investments (Q2 2026)
$3,341M
Total Assets (Q2 2026)
$35,882M
Long-Term Debt (Q2 2026)
$12,903M
Current Debt (Q2 2026)
$1,149M
Total Debt (Q2 2026)
$14,052M
Net Debt (Q2 2026)
$10,392M
Stockholders' Equity (Q2 2026)
$18,007M
Inventory (Q2 2026)
$4,605M
Working Capital (Q2 2026)
$12,513M
Dividends Paid (Q2 2026)
($1,295M)
Net Stock Issuance/Buyback (Q2 2026)
$418M
Gross PPE
$17.9B
FCF Yield
~1.35%
Operating Cash Flow TTM
~$8.7B
Q2 2026 Gross Margin
61.4%
Strengths
Concerns
Texas Instruments is emerging from a textbook analog/industrial semiconductor cyclical bottom, with Q2 2026 showing accelerating revenue growth (+22.8% YoY to $5.46B), expanding operating margins (34% to 42.6% in two quarters), and declining CapEx needs. The valuation is full (TTM P/E 43.9x, Forward P/E 27x) but justified by consensus expectations of 62% EPS recovery ($6.57 TTM to $10.64 forward), translating to a fair PEG of 1.03. The balance sheet is fortress-grade with $7B in cash and short-term investments, a 4.86x current ratio, and manageable net debt of $10.4B, while the company generates elite returns on equity (35.2%) and net margins (31.1%) from its defensible analog franchise. The primary risk is that the ambitious forward EPS recovery depends on sustained industrial and automotive demand, and any deceleration in Q3/Q4 2026 could trigger consensus cuts that expose the premium valuation.
Macro: The macro backdrop is defined by a hawkish Fed pricing 96% odds of zero rate cuts in 2026, creating a higher-for-longer rate regime that compresses equity multiples for cyclical/value names like TXN. Recession odds are collapsing (US at 6%, down 2pp WoW), supportive for industrial analog demand. Mortgage rates stuck near multi-year highs create headwinds for housing and consumer durables end markets. Commodities show stagflationary tilt with oil at ~$103/bbl and gold at $4,131.80 (+0.44%). Bond volatility elevated (classic blowup precursor), but recession odds low suggest regime-shift watch rather than imminent credit event. FRED macro data unavailable; calibration relies on news-derived signals and prediction markets.